Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-16

Clinical Trial Update: A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating JZP3507 (ONC206) in recurrent Grade 2 or 3 meningioma, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JZP3507 (ONC206) (ONC206)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Meningioma | Phase 2 | Status: NOT_YET_RECRUITING